To evaluate for differences in post-procedure 30-day encounters or infections following office cystoscopy using disposable versus reusable cystoscopes. Cystoscopies performed from June - September 2020 and February - May 2021 in our outpatient practice were retrospectively reviewed. The 2020 cystoscopies were performed with reusable cystoscopes and the 2021 cystoscopies were performed with disposable cystoscopes (Ambu Inc., Columbia, MD, USA). The primary outcome was the number of post-procedural 30-day encounters defined as phone calls, patient portal messages, emergency department visits, hospitalizations or clinic appointments related to post-procedural complications such as dysuria, hematuria, or fever. Culture-proven urinary tract infection within 30 days of cystoscopy was evaluated as a secondary outcome. We identified 1,000 cystoscopies, including 494 with disposable cystoscopes and 506 with reusable cystoscopes. Demographics were similar between groups. The most common indication for cystoscopy in both groups was suspicion of bladder cancer [disposable: 153 (30.2%) and reusable: 143 (28.9%)]. Reusable cystoscopes were associated with a higher number of 30-day encounters [35 (7.1%) vs. 11 (2.2%), P < .001], urine cultures [73 (14.8%) vs. 3 (0.6%), P = .005], and hospitalizations attributable to cystoscopy [1 (0.2%) vs. 0 (0%), P<.001] than the disposable scope group. Positive urine cultures were also significantly more likely after cystoscopy with a reusable cystoscope [17 (3.4%) vs. 1 (0.2%), P < .001]. Disposable cystoscopes were associated with a lower number of post-procedure encounters and positive urine cultures compared to reusable cystoscopes.
Bladder leiomyomas are rare, benign tumors with a variety of clinical presentations. Surgical approach is typically based on symptomatology and leiomyoma location. Literature on robotic excision is limited. We present our case of a unique transvesical approach. The patient had rapid convalescence with no complications, suggesting robotic transvesical excision is a safe, effective treatment for bladder leiomyoma for suitable candidates.
Objectives: To compare racial differences and pelvis dimensions between Caucasians and African Americans and to develop a risk calculator and scoring system to predict the risk of prolonged operative time and presence of PSM based on these dimensions. Materials and Methods: A retrospective review of 88 consecutive patients undergoing RALP with a pre-operative prostate MRI was conducted. Data extraction included demographic, perioperative, and postoperative oncologic outcomes. PSA was obtained within 3 months post-surgery. Wilcoxon rank sum and Fisher’s exact tests were used to compare continuous and categorical data, respectively. Single and multivariable regression analysis were used to determine contribution of each factor to the composite outcomes.. A risk score was created based on this analysis for predicting the composite outcome. Results: We identified 88 consecutive patients with localized prostate cancer that underwent a pre-operative prostate MRI. No statistically significant differences were found with respect to age, BMI or any post-operative outcome. PSA was lower at diagnosis (6.49 vs 9.72, p=0.006) and operative times were shorter in Caucasians.. Rates of PSM (13 vs 14, p=0.35), BCR (4 vs 2, p=0.69), and complications did not vary between the groups. Caucasians had wider/shallower pelvis dimensions. Based on these variables, we found that the log(odds of OR time >3 hours or PSM) = -5.333 + 1.158 (if African American) + 0.105*PSA + 0.076*F -0.035*G with an AUROCC=0.73. Using the predefined variables, patients can be risk stratified for PSM or prolonged operative times. Conclusions: Several pelvis dimensions were found to be shorter/narrower in African Americans and were associated with longer operative times. The presented risk calculator and stratification system may be used to predict prolonged operative time or having PSM.